3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
49
Nivolumab
22
Cyclophosphamide
20
fludarabine
13
Paclitaxel
9
Ipilimumab
9
atezolizumab
8
aldesleukin
8
Specimen Handling
8
Interleukin-2
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Biopsy
6
cemiplimab
5
fludarabine phosphate
4
durvalumab
4
Taxes
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
poly ICLC
3
epacadostat
3
X-Rays
3
Leucovorin
3
Injections
3
Immunoglobulin G
3
Filgrastim
3
Cisplatin
3
CTLA-4 Antigen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Technetium-99
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled